Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | STAT3 | P40763 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 7/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | CTSD | P07339 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9830646 | 0.85 | GAA (0.75) | SMN1; SMN2RAB9AGAALMNAPOLB | |
| SCHEMBL6467701 | 0.84 | SMN1; SMN2 (0.54) | NPC1SMN1; SMN2STAT3RAB9AGAA | |
| SCHEMBL6449862 | 0.80 | GAA (0.62) | NPC1SMN1; SMN2RAB9AGAALMNA | |
| SCHEMBL6453448 | 0.80 | NPC1 (1.00) | NPC1SMN1; SMN2STAT3RAB9AGAA | |
| SCHEMBL6470094 | 0.78 | LMNA (0.53) | NPC1SMN1; SMN2STAT3RAB9AGAA | |
| SCHEMBL6469344 | 0.78 | HSP90AA1 (0.79) | NPC1SMN1; SMN2STAT3RAB9ALMNA | |
| SCHEMBL12857990 | 0.78 | STAT3 (0.73) | NPC1SMN1; SMN2STAT3RAB9AGAA | |
| SCHEMBL6454315 | 0.78 | KAT6A (0.65) | NPC1SMN1; SMN2RAB9AGAALMNA | |
| SCHEMBL6450629 | 0.78 | GAA (0.64) | NPC1SMN1; SMN2RAB9AGAALMNA | |
| SCHEMBL22340646 | 0.77 | RXFP1 (0.60) | NPC1RAB9AGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | NPC1 59/4885SMN1; SMN2 4633/4885STAT3 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.